<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278445</url>
  </required_header>
  <id_info>
    <org_study_id>DOP22_3</org_study_id>
    <nct_id>NCT02278445</nct_id>
  </id_info>
  <brief_title>Evaluation of Pulmonary Doppler Signals in Patients With Systemic Sclerosis(SSc)</brief_title>
  <official_title>Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis (SSc)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Echosense Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Echosense Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler
      ultrasound system incorporating a special signal processing package- the Transthoracic
      Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel). Systemic sclerosis patients often
      develop pulmonary vascular disease leading to pulmonary hypertension. The TPD system may
      provide important insight into pulmonary blood vessels characteristics by the LDS (Lung
      Doppler Signals) signals that are related to pulmonary hypertension. The TPD performance in
      detecting PAH in SSc patients will be assessed in the study.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patients
  </why_stopped>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of SSc patients correctly identified with pulmonary hypertension severity in each of the 4 defined groups by RHC.</measure>
    <time_frame>12 month</time_frame>
    <description>Analyze Doppler data of 4 SSc groups (according to pulmonary hypertension severity) resulting in typical features. The features will be implemented in a pre-determined diagnostic algorithm that will determine the overall statistical success of the method in comparison to RHC data.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Systemic Sclerosis</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Doppler ultrasound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recording Doppler ultrasound noninvasively from the right chest wall</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Doppler ultrasound</intervention_name>
    <description>Recording Doppler ultrasound noninvasively from the right chest wall</description>
    <arm_group_label>Doppler ultrasound</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)</intervention_name>
    <arm_group_label>Doppler ultrasound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able and willing to give signed informed consent prior to enrollment

          2. Male or female, ≥ 18 years of age

          3. Diagnosis of SSc according to 2013 ACR/EULAR SSc Classification Criteria (van den
             Hoogen 2013): Score ≥ 9.

          4. Patients with RHC data available from measurement within 3 weeks prior to TPD
             assessment

          5. No change in or initiation of PAH specific therapy between the last RHC and TPD

        Exclusion Criteria:

          1. People unable or unwilling to give informed consent.

          2. PCWP or LVEDP &gt; 15 mmHg

          3. Any PH etiology outside Group 1 (Dana Point, 2008)

          4. Pregnant women

          5. Patients having severe chest wall deformity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merav Lidar, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba medical center, Rheumatology department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center, Pulmonology department</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <last_update_submitted>November 29, 2015</last_update_submitted>
  <last_update_submitted_qc>November 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic Sclerosis</keyword>
  <keyword>Pulmonary hypertension</keyword>
  <keyword>Lung Doppler Signals</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

